ProQR Therapeutics
PRQR
74 hedge funds and large institutions have $365M invested in ProQR Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 9 closing their positions.
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
10% more funds holding
Funds holding: 67 → 74 (+7)
9% more capital invested
Capital invested by funds: $333M → $365M (+$31.4M)
8.76% more ownership
Funds ownership: 62.19% → 70.95% (+8.8%)
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
17% less call options, than puts
Call options by funds: $485K | Put options by funds: $584K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$9.89M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.31M |
| 3 |
RI
RTW Investments
New York
|
+$4.45M |
| 4 |
Goldman Sachs
New York
|
+$3.67M |
| 5 |
BlackRock
New York
|
+$3.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.2M |
| 2 |
KA
Kerrisdale Advisers
Miami,
Florida
|
-$3.33M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.52M |
| 4 |
JP Morgan Chase
New York
|
-$1.84M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.61M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
76
Altium Capital Management
New York
| – | -$1.05M | -125,000 | Closed |
|
|
APP
77
Alpha Paradigm Partners
Chicago,
Illinois
| – | -$371K | -44,323 | Closed |
|
|
BFM
78
Boothbay Fund Management
New York
| – | -$152K | -18,191 | Closed |
|
79
Squarepoint
New York
| – | -$151K | -18,049 | Closed |
|
80
Two Sigma Advisers
New York
| – | -$106K | -12,700 | Closed |
|
81
Ameriprise
Minneapolis,
Minnesota
| – | -$94K | -11,200 | Closed |
|
82
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$63K | -7,500 | Closed |
|
83
Barclays
London,
United Kingdom
| – | -$23 | -3 | -13% |
|
PRQR Hedge Fund Activity: Q4 2021 in Review
74 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2021, worth a combined $365M — up 9.4% from $333M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PRQR positions and 9 closed out — a net gain of 9 holders — while 25 added to existing stakes and 24 trimmed.
The largest buyer was Cowen and Company, adding an estimated $9.89M. The largest seller was Wellington Management Group, cutting an estimated $10.2M.
- 74 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2021, up from 67 in Q3 2021.
- Funds reported $365M of ProQR Therapeutics stock for Q4 2021, up 9.4% quarter-over-quarter.
- 18 funds opened new ProQR Therapeutics positions in Q4 2021 and 9 closed out, a net change of +9 holders.
- The largest ProQR Therapeutics buyer in Q4 2021 was Cowen and Company, an estimated $9.89M added.
- The largest ProQR Therapeutics seller in Q4 2021 was Wellington Management Group, an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2021.